CA2795158C - Formulations transdermiques empechant les abus constituees d'agonistes et d'agonistes/antagonistes d'opiaces - Google Patents

Formulations transdermiques empechant les abus constituees d'agonistes et d'agonistes/antagonistes d'opiaces Download PDF

Info

Publication number
CA2795158C
CA2795158C CA2795158A CA2795158A CA2795158C CA 2795158 C CA2795158 C CA 2795158C CA 2795158 A CA2795158 A CA 2795158A CA 2795158 A CA2795158 A CA 2795158A CA 2795158 C CA2795158 C CA 2795158C
Authority
CA
Canada
Prior art keywords
opioid
antagonist
prodrug
mil
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2795158A
Other languages
English (en)
Other versions
CA2795158A1 (fr
Inventor
Audra Lynn Stinchcomb
Guohua Li
Stan Lee Banks
Jeffery Lynn Howard
Miroslaw Jerzy Golinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buzzz Pharmaceuticals Ltd
Original Assignee
Buzzz Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buzzz Pharmaceuticals Ltd filed Critical Buzzz Pharmaceuticals Ltd
Publication of CA2795158A1 publication Critical patent/CA2795158A1/fr
Application granted granted Critical
Publication of CA2795158C publication Critical patent/CA2795158C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des timbres transdermiques multi-couches empêchant les abus. Lesdits timbres comprennent des opioïdes et des promédicaments opioïdes qui possèdent une couche barrière située entre la couche contenant l'opioïde ou le promédicament opioïde et une couche contenant un antagoniste d'opioïde ou un promédicament d'antagoniste d'opioïde.
CA2795158A 2010-04-02 2011-04-04 Formulations transdermiques empechant les abus constituees d'agonistes et d'agonistes/antagonistes d'opiaces Active CA2795158C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32052610P 2010-04-02 2010-04-02
US61/320,526 2010-04-02
PCT/US2011/031135 WO2011123866A1 (fr) 2010-04-02 2011-04-04 Formulations transdermiques empêchant les abus constituées d'agonistes et d'agonistes/antagonistes d'opiacés

Publications (2)

Publication Number Publication Date
CA2795158A1 CA2795158A1 (fr) 2011-10-06
CA2795158C true CA2795158C (fr) 2019-10-22

Family

ID=44121770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795158A Active CA2795158C (fr) 2010-04-02 2011-04-04 Formulations transdermiques empechant les abus constituees d'agonistes et d'agonistes/antagonistes d'opiaces

Country Status (6)

Country Link
US (1) US8481560B2 (fr)
EP (2) EP2552425B1 (fr)
JP (2) JP2013523780A (fr)
CA (1) CA2795158C (fr)
ES (1) ES2592277T3 (fr)
WO (1) WO2011123866A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
WO2011009602A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique extrudée à chaud à libération contrôlée
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
EP2552425B1 (fr) 2010-04-02 2016-07-27 Buzzz Pharmaceuticals Limited Formulations transdermiques inviolables d'agonistes et d'agonistes-antagonistes d'opiacés
EP2552924B1 (fr) * 2010-04-02 2015-09-16 Zynerba Pharmaceuticals, Inc. Prodrogues opioïdes administrables par voie transdermique, compositions anti-abus et méthodes d'utilisation de prodrogues opioïdes
CA2808219C (fr) 2010-09-02 2019-05-14 Gruenenthal Gmbh Forme pharmaceutique inviolable comportant un sel inorganique
WO2012028318A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un polymère anionique
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130211351A1 (en) * 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
KR102196741B1 (ko) 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) * 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
EP3073994A1 (fr) 2013-11-26 2016-10-05 Grünenthal GmbH Préparation de composition pharmaceutique en poudre par cryo-broyage
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
EP3142646A1 (fr) 2014-05-12 2017-03-22 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
US10238648B2 (en) 2014-07-18 2019-03-26 Buzzz Pharmaceuticals Ltd. Abuse deterrent opioid/opioid-antagonist transdermal patch
WO2016064873A1 (fr) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
US10010543B1 (en) * 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (fr) 2015-09-10 2017-03-16 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
GB201600919D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
GB201600920D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
WO2017159033A1 (fr) 2016-03-16 2017-09-21 テルモ株式会社 Stent
EP3565617A1 (fr) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Dispositifs et methodes d'administration transdermique de medicament
WO2019032147A1 (fr) * 2017-08-10 2019-02-14 Avro Life Sciences, Inc. Système d'administration transdermique de médicament
US20180193332A1 (en) * 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
WO2019090125A2 (fr) * 2017-11-02 2019-05-09 Chrono Therapeutics Inc. Système d'administration de médicament transdermique anti-abus intelligent
US12364668B2 (en) * 2017-11-15 2025-07-22 The Regents Of The University Of California Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
EP3801732A4 (fr) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Procédés et systèmes d'administration de médicament
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
JP7603583B2 (ja) * 2018-10-18 2024-12-20 アビオール、インコーポレイテッド 慢性腎疾患随伴掻痒を処置する方法及びデバイス
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US11389409B2 (en) 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216301A (en) 1964-01-27 1965-11-09 Bevis Ind Inc Edge trimming apparatus
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4591622A (en) 1984-10-29 1986-05-27 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product thereof
US4585836A (en) 1984-10-29 1986-04-29 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product with improved lap-shear stability-II
US4584355A (en) 1984-10-29 1986-04-22 Dow Corning Corporation Silicone pressure-sensitive adhesive process and product with improved lap-shear stability-I
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
DK1079813T3 (da) * 1998-04-29 2005-06-06 Virotex Corp Farmaceutisk bæreranordning, der er egnet til administration af farmaceutiske forbindelser til slimhindeoverflader
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
SI2062573T1 (sl) * 2001-05-01 2012-02-29 Euro Celtique Sa Proti zlorabi odporni transdermalni sistemi, ki vsebujejo opioid
IL159415A0 (en) 2001-06-18 2004-06-01 Noven Pharma Enhanced drug delivery in transdermal systems
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
AR033748A1 (es) * 2002-05-15 2004-01-07 Thalas Group Inc Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
CA2543610A1 (fr) * 2003-10-30 2005-05-19 Alza Corporation Systemes analgesiques transdermiques reduisant les risques d'abus de consommation
HRP20090363T1 (hr) * 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
WO2008134071A1 (fr) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Formulations multimodales à libération progressive résistantes aux emplois abusifs
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
BRPI0619806A2 (pt) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
SI2719378T1 (sl) * 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080008745A1 (en) 2006-06-21 2008-01-10 University Of Kentucky Research Foundation Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
ES2549115T3 (es) * 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
US8653271B2 (en) 2006-10-18 2014-02-18 University Of Kentucky Research Foundation Enhancing transdermal delivery of opioid antagonists and agonists using codrugs linked to bupropion or hydroxybupropion
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
HUE043555T2 (hu) 2007-11-30 2019-09-30 Zynerba Pharmaceuticals Inc Tetrahidrokannabinol gyógyszer elõanyagai (prodrugjai), kompozíciók, amelyek tetrahidrokannabinol gyógyszer elõanyagait tartalmazzák, és eljárások, ezek alkalmazására
EP2254561A2 (fr) * 2008-03-26 2010-12-01 AllTranz Inc. Formulations transdermiques inviolables d agonistes et d agonistes-antagonistes d opiacés
EP2552425B1 (fr) 2010-04-02 2016-07-27 Buzzz Pharmaceuticals Limited Formulations transdermiques inviolables d'agonistes et d'agonistes-antagonistes d'opiacés

Also Published As

Publication number Publication date
WO2011123866A1 (fr) 2011-10-06
JP2016053085A (ja) 2016-04-14
CA2795158A1 (fr) 2011-10-06
JP2013523780A (ja) 2013-06-17
EP2552425B1 (fr) 2016-07-27
EP2552425A1 (fr) 2013-02-06
JP6212104B2 (ja) 2017-10-11
US8481560B2 (en) 2013-07-09
EP3064199B1 (fr) 2023-12-20
US20110245783A1 (en) 2011-10-06
ES2592277T3 (es) 2016-11-29
EP3064199A1 (fr) 2016-09-07

Similar Documents

Publication Publication Date Title
CA2795158C (fr) Formulations transdermiques empechant les abus constituees d'agonistes et d'agonistes/antagonistes d'opiaces
US20090246265A1 (en) Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2955247C (fr) Timbre transdermique a base d'opioides/d'antagoniste des opioides destine a eviter tout usage abusif
KR101407131B1 (ko) 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템
JP5329461B2 (ja) 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
KR100742471B1 (ko) 활성 물질 디아모르핀을 포함하는 약학 제제 및 아편제중독증의 치료 방법에서의 그의 용도
US20190328681A1 (en) Transdermal patch
CA2795156C (fr) Prodrogues opioides administrables par voie transdermique, compositions anti-abus et methodes d'utilisation de prodrogues opioides
KR20060120678A (ko) 남용될 가능성이 감소된 경피용 진통제 시스템
EP1996172B1 (fr) Emballage pour pansement
KR20180074797A (ko) 통증 치료를 위한 오피오이드 작용제 및 오피오이드 길항제의 비-경피 전달된 n-옥시드 유도체를 포함하는 남용 방지 경피 전달 장치 및 조성물
AU2016298761A1 (en) Transdermal delivery system

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160128

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107